TY - JOUR
T1 - The Promise of Multicancer Early Detection. Comment on Pons-Belda et al. Can Circulating Tumor DNA Support a Successful Screening Test for Early Cancer Detection? The Grail Paradigm. Diagnostics 2021, 11, 2171
AU - Klein, Eric A.
AU - Beer, Tomasz M.
AU - Seiden, Michael
N1 - Publisher Copyright:
© 2022 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2022/5
Y1 - 2022/5
N2 - Multicancer Early Detection (MCED) represents a new and exciting paradigm for the early detection of cancer, which is the leading cause of death worldwide. Current screening tests, recommended for only five cancer types (breast, lung, colon, cervical, and prostate), are limited by a lack of complete adherence to guideline-based use and by the fact that they have cumulative high false positive rates. MCED tests agnostically detect cancer signals in the blood with good sensitivity and low false positive rates, can predict the cancer site of origin with high accuracy, can detect highly lethal cancers that have no current screening tests, and promise to improve cancer screening by improving efficiency and reducing the overall number needed to screen. Herein we outline this promise and clarify several published misconceptions about this field.
AB - Multicancer Early Detection (MCED) represents a new and exciting paradigm for the early detection of cancer, which is the leading cause of death worldwide. Current screening tests, recommended for only five cancer types (breast, lung, colon, cervical, and prostate), are limited by a lack of complete adherence to guideline-based use and by the fact that they have cumulative high false positive rates. MCED tests agnostically detect cancer signals in the blood with good sensitivity and low false positive rates, can predict the cancer site of origin with high accuracy, can detect highly lethal cancers that have no current screening tests, and promise to improve cancer screening by improving efficiency and reducing the overall number needed to screen. Herein we outline this promise and clarify several published misconceptions about this field.
KW - circulating cell-free genome atlas
KW - methylation
KW - multicancer early detection
UR - http://www.scopus.com/inward/record.url?scp=85130710357&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85130710357&partnerID=8YFLogxK
U2 - 10.3390/diagnostics12051243
DO - 10.3390/diagnostics12051243
M3 - Comment/debate
AN - SCOPUS:85130710357
SN - 2075-4418
VL - 12
JO - Diagnostics
JF - Diagnostics
IS - 5
M1 - 1243
ER -